Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina
tive effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Rossana E. Chahla, MD, PhD 1 Luis Medina Ruiz, MD 2 Eugenia S. Ortega, MSc 3 Marcelo F. Morales, RN 4 Francisco Barreiro, MD 5 Alexia George, MD 5 Cesar Mancilla, RN 4 Sylvia D' Amato, RN 4 Guillermo Barrenechea, MSc 3 Daniel G. Goroso, PhD
References
Abd-Elsalam, Noor, Badawi, Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study
Alam, Murshed, Gomes, Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in dhakaan observational study, Eur J Med Heal Sci
Ashburn, Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat Rev Drug Discov
Caly, Druce, Catton, Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect , the company' s public news and information, Antivir Res
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antivir Res
Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: a pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine
Chaccour, Ruiz-Castillo, Richardson, The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate the potential of ivermectin to reduce covid-19 transmission in low risk, non-severe covid-19 patients in the first 48 hours after symptoms onset: a structured summary of a study protocol, Trials
Chahla, Prophylaxis covid-19 in health workers through intensive treatment with ivermectin and iotacarrageenan (Ivercar-Tuc), ClinicalTrials
Chong, Sullivan, New uses for old drugs, Nature
H Ector, Roberto, Psaltis, Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Investig
Hirsch, Hector, Covid 19 and ivermectin prevention and treatment update, J Infect Dis Trav Med
Kory, Meduri, Varon, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial, EClinicalMedicine
Liu, Fang, Reagan, In silico drug repositioning: what we need to know, Drug Discov Today
Shouman, Hegazy, Nafae, Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial, J Clin Diagn Res
{ 'indexed': {'date-parts': [[2022, 7, 11]], 'date-time': '2022-07-11T06:51:07Z', 'timestamp': 1657522267235},
'reference-count': 18,
'publisher': 'Ovid Technologies (Wolters Kluwer Health)',
'issue': '5',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'DOI': '10.1097/mjt.0000000000001433',
'type': 'journal-article',
'created': {'date-parts': [[2021, 9, 2]], 'date-time': '2021-09-02T00:35:39Z', 'timestamp': 1630542939000},
'page': 'e601-e604',
'source': 'Crossref',
'is-referenced-by-count': 5,
'title': 'Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for '
'COVID-19 in Health Care Workers From Tucuman, Argentina',
'prefix': '10.1097',
'volume': '28',
'author': [ {'given': 'Rossana E.', 'family': 'Chahla', 'sequence': 'first', 'affiliation': []},
{'given': 'Luis', 'family': 'Medina Ruiz', 'sequence': 'additional', 'affiliation': []},
{'given': 'Eugenia S.', 'family': 'Ortega', 'sequence': 'additional', 'affiliation': []},
{'given': 'Marcelo F.', 'family': 'Morales, RN', 'sequence': 'additional', 'affiliation': []},
{'given': 'Francisco', 'family': 'Barreiro', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alexia', 'family': 'George', 'sequence': 'additional', 'affiliation': []},
{'given': 'Cesar', 'family': 'Mancilla, RN', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sylvia', 'family': "D' Amato, RN", 'sequence': 'additional', 'affiliation': []},
{'given': 'Guillermo', 'family': 'Barrenechea', 'sequence': 'additional', 'affiliation': []},
{'given': 'Daniel G.', 'family': 'Goroso', 'sequence': 'additional', 'affiliation': []},
{'given': 'Maria', 'family': 'Peral de Bruno', 'sequence': 'additional', 'affiliation': []}],
'member': '276',
'published-online': {'date-parts': [[2021, 9]]},
'reference': [ { 'key': 'R1-20210907',
'doi-asserted-by': 'crossref',
'first-page': '645',
'DOI': '10.1038/448645a',
'article-title': 'New uses for old drugs',
'volume': '448',
'author': 'Chong',
'year': '2007',
'journal-title': 'Nature.'},
{ 'key': 'R2-20210907',
'doi-asserted-by': 'crossref',
'first-page': '110',
'DOI': '10.1016/j.drudis.2012.08.005',
'article-title': 'In silico drug repositioning: what we need to know',
'volume': '18',
'author': 'Liu',
'year': '2013',
'journal-title': 'Drug Discov Today'},
{ 'key': 'R3-20210907',
'doi-asserted-by': 'crossref',
'first-page': '673',
'DOI': '10.1038/nrd1468',
'article-title': 'Drug repositioning: identifying and developing new uses for existing '
'drugs',
'volume': '3',
'author': 'Ashburn',
'year': '2004',
'journal-title': 'Nat Rev Drug Discov.'},
{ 'key': 'R4-20210907',
'doi-asserted-by': 'crossref',
'first-page': '202',
'DOI': '10.1016/j.antiviral.2012.06.008',
'article-title': 'Nuclear trafficking of proteins from RNA viruses: potential target for '
'antivirals?',
'volume': '95',
'author': 'Caly',
'year': '2012',
'journal-title': 'Antivir Res'},
{ 'key': 'R5-20210907',
'doi-asserted-by': 'crossref',
'first-page': '104787',
'DOI': '10.1016/j.antiviral.2020.104787',
'article-title': 'Since January 2020 Elsevier has created a COVID-19 resource centre with '
'free information in English and Mandarin on the novel coronavirus '
'COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect , '
"the company' s public news and information",
'volume': '178',
'author': 'Caly',
'year': '2020',
'journal-title': 'Antivir Res'},
{ 'key': 'R6-20210907',
'doi-asserted-by': 'crossref',
'first-page': 'e299',
'DOI': '10.1097/MJT.0000000000001377',
'article-title': 'Review of the emerging evidence demonstrating the efficacy of '
'ivermectin in the prophylaxis and treatment of COVID-19',
'volume': '28',
'author': 'Kory',
'year': '2021',
'journal-title': 'Am J Ther.'},
{ 'key': 'R7-20210907',
'doi-asserted-by': 'crossref',
'first-page': '100720',
'DOI': '10.1016/j.eclinm.2020.100720',
'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms '
'and humoral response in patients with non-severe COVID-19: a pilot, '
'double-blind, placebo-controlled, randomized clinical trial',
'volume': '3',
'author': 'Chaccour',
'year': '2021',
'journal-title': 'EClinicalMedicine.'},
{ 'key': 'R8-20210907',
'doi-asserted-by': 'crossref',
'first-page': '100959',
'DOI': '10.1016/j.eclinm.2021.100959',
'article-title': 'Antiviral effect of high-dose ivermectin in adults with COVID-19: A '
'proof-of-concept randomized trial',
'volume': '37',
'author': 'Krolewiecki',
'year': '2021',
'journal-title': 'EClinicalMedicine.'},
{ 'key': 'R9-20210907',
'doi-asserted-by': 'crossref',
'first-page': '1007',
'DOI': '10.31546/2633-8653.1007',
'article-title': 'Study of the efficacy and safety of topical ivermectin + '
'iota-carrageenan in the prophylaxis against COVID-19 in health '
'personnel',
'volume': '2',
'author': 'Héctor',
'year': '2020',
'journal-title': 'J Biomed Res Clin Investig.'},
{ 'key': 'R10-20210907',
'first-page': '1',
'article-title': 'Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare '
'providers in a selected tertiary hospital in dhaka—an observational '
'study',
'volume': '2',
'author': 'Alam',
'year': '2020',
'journal-title': 'Eur J Med Heal Sci.'},
{ 'key': 'R11-20210907',
'first-page': '27',
'article-title': 'Use of ivermectin as a potential chemoprophylaxis for COVID-19 in '
'Egypt: a randomized clinical trial',
'volume': '15',
'author': 'Shouman',
'year': '2021',
'journal-title': 'J Clin Diagn Res.'},
{ 'key': 'R12-20210907',
'first-page': 'NCT047017',
'article-title': 'Prophylaxis covid-19 in health workers through intensive treatment with '
'ivermectin and iota-carrageenan (Ivercar-Tuc)',
'volume': '20',
'author': 'Chahla',
'year': '2020',
'journal-title': 'ClinicalTrials.gov.'},
{ 'key': 'R13-20210907',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1186/s13063-020-04421-z',
'article-title': 'The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate '
'the potential of ivermectin to reduce covid-19 transmission in low '
'risk, non-severe covid-19 patients in the first 48 hours after symptoms '
'onset: a structured summary of a study protocol',
'volume': '21',
'author': 'Chaccour',
'year': '2020',
'journal-title': 'Trials'},
{ 'key': 'R14-20210907',
'first-page': '1',
'article-title': 'Covid 19 and ivermectin prevention and treatment update',
'volume': '4',
'author': 'Hirsch',
'year': '2020',
'journal-title': 'J Infect Dis Trav Med.'},
{ 'key': 'R15-20210907',
'article-title': 'Clinical study evaluating the efficacy of ivermectin in COVID-19 '
'treatment: A randomized controlled study [published online ahead of '
'print, 2021 Jun 2]',
'author': 'Abd-Elsalam',
'year': '2021',
'journal-title': 'J Med Virol.'},
{ 'key': 'R16-20210907',
'doi-asserted-by': 'crossref',
'first-page': '23',
'DOI': '10.1186/s12941-020-00368-w',
'article-title': 'Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19',
'volume': '19',
'author': 'Sharun',
'year': '2020',
'journal-title': 'Ann Clin Microbiol Antimicrob.'},
{ 'key': 'R17-20210907',
'doi-asserted-by': 'crossref',
'first-page': '611',
'DOI': '10.3906/sag-2004-145',
'article-title': 'Antiviral treatment of covid-19',
'volume': '50',
'author': 'Şimşek Yavuz',
'year': '2020',
'journal-title': 'Turkish J Med Sci.'},
{ 'key': 'R18-20210907',
'doi-asserted-by': 'crossref',
'first-page': 'e434',
'DOI': '10.1097/MJT.0000000000001402',
'article-title': 'Ivermectin for Prevention and Treatment of COVID-19 Infection: A '
'Systematic Review, Meta-analysis, and Trial Sequential Analysis to '
'Inform Clinical Guidelines',
'volume': '28',
'author': 'Bryant',
'year': '2021',
'journal-title': 'Am J Ther.'}],
'container-title': 'American Journal of Therapeutics',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001433',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 9, 7]],
'date-time': '2021-09-07T20:00:46Z',
'timestamp': 1631044846000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/MJT.0000000000001433'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 8, 16]]},
'references-count': 18,
'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2021]]}},
'URL': 'http://dx.doi.org/10.1097/MJT.0000000000001433',
'relation': {},
'ISSN': ['1075-2765'],
'subject': ['Pharmacology (medical)', 'Pharmacology', 'General Medicine'],
'published': {'date-parts': [[2021, 8, 16]]}}